Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vicarious Surgical Inc. (RBOT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public surgical robotics and medical device developer. These filings offer detailed information on the Vicarious Surgical System, the company’s operating expenses, capital structure, governance and listing status.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Vicarious Surgical presents audited and interim financial statements, segment information for research and development, sales and marketing, and general and administrative activities, along with risk factors and management’s discussion of its development-stage business. Current reports on Form 8-K disclose material events such as registered direct offerings and private placements of common stock and warrants, at-the-market offering agreements, cash burn guidance, board and committee changes, and special meetings of stockholders to approve warrant exercises under New York Stock Exchange rules.
Filings also document listing and registration matters. For example, a Form 25 filed by the New York Stock Exchange relates to the removal from listing and registration of Vicarious Surgical’s publicly traded warrants, while separate 8-K items describe the NYSE’s notice to commence delisting proceedings for those warrants and the continued listing of the company’s Class A common stock under the symbol RBOT, subject to compliance with NYSE standards.
On Stock Titan, these documents are supplemented by AI-powered summaries that explain the key points of lengthy filings, such as complex financing terms, warrant structures, or at-the-market programs. Users can quickly see highlights from 10-K and 10-Q reports, understand the implications of Form 8-K events, and review proxy materials like definitive proxy statements (DEF 14A) that cover special meetings and stockholder proposals. The page also links to information about warrants, capital raises and other securities-related disclosures, helping investors and researchers analyze how Vicarious Surgical funds and governs the development of its single-port robotic surgery platform.
Vicarious Surgical Inc. is asking stockholders to approve a reverse stock split of its Class A and Class B common stock, at a ratio between 1‑for‑2 and 1‑for‑30, with the exact ratio and timing to be set later by the board of directors or abandoned entirely.
The main goal is to raise the per‑share price of Class A stock to help qualify for an uplisting to the Nasdaq Capital Market after the New York Stock Exchange suspended trading and began delisting proceedings for failing to meet its $15 million market capitalization standard. The company’s Class A shares now trade on the OTC Markets under the symbol “RBOT.”
The proxy explains that a reverse split would reduce outstanding shares, proportionately adjust options, warrants and other equity awards, and pay cash instead of issuing fractional shares. It also notes potential risks, including no guarantee of a higher or sustained share price and possible lower trading liquidity, while authorized share counts would remain unchanged, increasing the number of shares available for future issuance.
Vicarious Surgical Inc. notified the New York Stock Exchange LLC to remove its Class A Common Stock from listing and/or registration. The Exchange states it has complied with rules to strike the class and the issuer "has complied with its rules of the Exchange" governing the voluntary withdrawal.
Vicarious Surgical Inc. is asking shareholders to approve an amendment to its Certificate of Incorporation to authorize a reverse stock split of Class A and Class B common stock at a ratio of not less than 1-for-2 and not greater than 1-for-30, with the Board to select the exact ratio and timing if approved.
The Board approved the proposal on March 13, 2026 and recommends approval. The company says the primary intent is to raise the per-share trading price of Class A common stock to help meet Nasdaq initial listing bid-price requirements, after the NYSE suspended trading and commenced delisting proceedings; Class A shares currently trade on the OTCID tier under symbol RBOT. The proxy discloses February 28, 2026 outstanding totals of 6,468,185 shares of Class A common stock and 653,990 shares of Class B common stock for beneficial ownership calculations. The Board may abandon the amendment at any time prior to filing the Certificate of Amendment. Approval requires the affirmative vote of a majority of votes cast.
Vicarious Surgical Inc. reported continued operating losses and confirmed that its common stock has been delisted from the New York Stock Exchange and is now quoted on the OTCID market.
For 2025, the company posted a net loss of $50.2 million, lower than the $63.2 million net loss in 2024. Total operating expenses fell to $50.0 million from $66.6 million, reflecting reduced research and development and general and administrative spending.
Liquidity weakened materially: cash and cash equivalents were $2.6 million and short-term investments $7.2 million at December 31, 2025, down from $9.7 million and $39.4 million a year earlier. Total assets declined to $19.6 million and stockholders’ equity to $9.8 million, from $67.7 million and $46.7 million respectively.
The NYSE delisted the shares after the company’s average global market capitalization over 30 trading days fell below $15 million. The company chose not to appeal, obtained OTCID quotation on March 4, 2026 under the symbol RBOT, and has applied to upgrade to the OTCQB market, with no assurance on future trading liquidity.
Vicarious Surgical Inc. is a pre-revenue medical device company developing the single-port Vicarious Surgical System, a robotic platform intended for minimally invasive ventral hernia and other abdominal procedures, which has not yet been authorized by the FDA.
The company ended December 31, 2025 with cash and cash equivalents of $2.6 million and short-term investments of $7.2 million, and an accumulated deficit of $246.1 million. Management believes these resources, after a March 6, 2026 headcount reduction, will fund operations only through the second quarter of 2026, creating substantial doubt about its ability to continue as a going concern.
On March 3, 2026, the New York Stock Exchange determined to suspend trading and commence delisting proceedings for Vicarious Surgical’s Class A common stock for failing to maintain a $15.0 million average global market capitalization requirement. The shares now trade on the OTCID market tier under the symbol RBOT, a significantly more limited market that may reduce liquidity and pressure the stock price.
Vicarious Surgical Inc. reported changes to executive compensation for two senior leaders. On March 4, 2026, the company entered into amendments to the Executive Employment Agreements for Adam Sachs, its President, and Sammy Khalifa, its Chief Technology Officer.
Under these amendments, Mr. Sachs agreed to voluntarily reduce his annual base salary to approximately $270,810, and Mr. Khalifa agreed to reduce his annual base salary to approximately $318,600. Despite these reductions, any target bonus amounts and severance payments under their employment agreements will continue to be calculated using the higher base salaries that were in effect immediately before these amendments. The amendments are filed as Exhibits 10.1 and 10.2.
Vicarious Surgical Inc. reports that the New York Stock Exchange has suspended trading in its common stock and begun proceedings to delist it. The NYSE determined the company no longer meets the continued listing requirement for an average global market capitalization of at least $15,000,000 over 30 trading days.
The company has received approval to have its shares quoted on the OTCID market operated by OTC Markets, and expects trading there to begin on March 4, 2026 under the symbol RBOT. Management notes that OTC quotation is a significantly more limited and less liquid market, which may reduce trading activity, pressure the share price, hinder equity fundraising, limit access to public capital markets, and weaken the company’s ability to offer equity incentives to employees.
Sammy Khalifa reported intent to sell Class A common stock with a listed sale date of 03/02/2026 described as a Restricted Stock Lapse. The excerpt also lists prior securities sold in the past three months: 239 shares on 12/03/2025 and 754 shares on 02/20/2026.
This Form 144 notice names the security as Class A Common Stock and shows broker details for UBS Financial Services. The filing is a routine insider disposition notice stating planned and recent transactions; timing and proceeds detail beyond the dates and share counts above are not shown in the excerpt.
Vicarious Surgical Inc filed a Form 144 reporting a proposed sale of 1,348 shares of Class A common stock.
The filing lists the sale method as Restricted Stock Lapse dated 03/02/2026 and names UBS Financial Services Inc. It also discloses prior sales of 463 shares on 12/03/2025 and 942 shares on 02/20/2026.
Vicarious Surgical Inc. President and director Adam David Sachs reported an open-market sale of 942 shares of Class A Common Stock on February 20, 2026, at a weighted average price of $2.0878 per share. After this transaction, he held 46,943 shares directly.
The sale was executed under a mandated “sell to cover” arrangement to satisfy tax withholding obligations from vesting restricted stock units granted on May 19, 2022, and did not represent a discretionary trade by Sachs.